公开(公告)号：US10548877B2

公开(公告)日：2020-02-04

申请号：US16083295

申请日：2017-03-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masaki Ogino ,  Eiji Kimura ,  Shinkichi Suzuki ,  Kouji Fuji ,  Tomohiro Ohashi ,  Makoto Fushimi ,  Kei Masuda ,  Tatsuki Koike ,  Takeshi Wakabayashi ,  Jinichi Yonemori ,  Masami Yamada

IPC: A61K31/4192 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4406 ,  A61K31/4439 ,  A61P25/20 ,  A61P25/28 ,  A61P25/18 ,  A61P25/16 ,  C07D213/56 ,  C07D231/12 ,  C07D249/06 ,  C07D401/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12

Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.

公开(公告)号：US20150266872A1

公开(公告)日：2015-09-24

申请号：US14435899

申请日：2013-10-15

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Masato Yoshikawa ,  Izumi Nomura ,  Yoshiteru Ito ,  Eiji Kimura ,  Tomoaki Hasui ,  Haruhi Ando ,  Hiromi Fukuda ,  Toshiya Nishi

IPC: C07D471/04 ,  C07D519/00 ,  C07D413/04

CPC classification number: C07D471/04 ,  C07D413/04 ,  C07D519/00

Abstract: The present invention provides a compound or a salt thereof useful for an agent for the prophylaxis or treatment of neurodegenerative disease and the like. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Abstract translation: 本发明提供可用于预防或治疗神经变性疾病等的药剂的化合物或其盐。 本发明涉及由下式表示的化合物，其中每个符号如本说明书中所定义，或其盐。

公开(公告)号：US11987586B1

公开(公告)日：2024-05-21

申请号：US18497602

申请日：2023-10-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yasushi Hattori ,  Marilena Pira ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Eiji Kimura ,  Norihito Tokunaga ,  Shuhei Ikeda ,  Martin Alexander Pawliczek ,  Noriyuki Tezuka ,  Yasutaka Hoashi ,  Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike

IPC: C07D487/04 ,  A61P25/00 ,  C07D413/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61P25/00 ,  C07D413/04 ,  C07D519/00

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10112956B2

公开(公告)日：2018-10-30

申请号：US15467548

申请日：2017-03-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Yuichi Kajita ,  Masato Yoshikawa ,  Shuhei Ikeda ,  Eiji Kimura ,  Tomoaki Hasui ,  Toshiya Nishi ,  Hiromi Fukuda

IPC: C07D498/08 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D471/10 ,  C07D405/14 ,  C07D213/74 ,  C07D239/42 ,  C07D401/04 ,  C07D401/14 ,  C07D487/18 ,  C07D401/12 ,  C07D413/04 ,  C07D417/04 ,  C07D451/02 ,  C07D451/04 ,  C07D487/10 ,  C07D491/18 ,  C07D403/12 ,  C07D491/08 ,  C07D403/04 ,  C07D403/14 ,  C07D405/12 ,  C07D213/12 ,  A61K9/20 ,  A61K9/48 ,  C07D213/72 ,  C07D487/08 ,  C12N9/99

Abstract: An object of the present invention is to provide a compound having a superior CH24H inhibitory action, which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US11230541B2

公开(公告)日：2022-01-25

申请号：US16634402

申请日：2018-07-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Masaki Ogino ,  Yasuhisa Kohara ,  Tomoko Ohashi ,  Tomohiro Kaku ,  Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito

IPC: C07D409/12 ,  C07D401/12 ,  C07D249/18 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US10548899B2

公开(公告)日：2020-02-04

申请号：US15769295

申请日：2016-10-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Takahiro Sugimoto ,  Shinkichi Suzuki ,  Hiroki Sakamoto ,  Masami Yamada ,  Minoru Nakamura ,  Makoto Kamata ,  Kenichiro Shimokawa ,  Masaki Ogino ,  Eiji Kimura ,  Masataka Murakami ,  Takuto Kojima ,  Jinichi Yonemori

IPC: A61K31/53 ,  A61K31/517 ,  C07D403/06 ,  C07D403/10 ,  C07D405/14 ,  C07D401/14 ,  C07D239/88 ,  C07D401/06 ,  A61P25/28 ,  A61P25/04 ,  A61P25/18 ,  A61P25/16

Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.

公开(公告)号：US10202376B2

公开(公告)日：2019-02-12

申请号：US15538297

申请日：2015-12-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Yuhei Miyanohana ,  Masaki Ogino ,  Yuta Tanaka ,  Makoto Fushimi ,  Tomohiro Okawa ,  Yuki Hanya ,  Tatsuki Koike

IPC: C07D471/04 ,  A61K31/437 ,  C07D487/04 ,  A61P25/00 ,  A61P29/00

Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

公开(公告)号：US11713311B2

公开(公告)日：2023-08-01

申请号：US17550173

申请日：2021-12-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Masaki Ogino ,  Yasuhisa Kohara ,  Tomoko Ohashi ,  Tomohiro Kaku ,  Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito

IPC: C07D409/12 ,  C07D401/12 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18

CPC classification number: C07D409/12 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2095 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61P25/06 ,  A61P25/24 ,  A61P25/28 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18 ,  C07D401/12

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I):




wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US10214508B2

公开(公告)日：2019-02-26

申请号：US15318552

申请日：2015-06-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki Ogino ,  Eiji Kimura ,  Shinkichi Suzuki ,  Tomoko Ashizawa ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Ryosuke Arai

IPC: C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  C07D213/81 ,  C07D405/12

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

公开(公告)号：US09624184B2

公开(公告)日：2017-04-18

申请号：US14781665

申请日：2014-04-03

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Tatsuki Koike ,  Masato Yoshikawa ,  Izumi Nomura ,  Yoshiteru Ito ,  Eiji Kimura ,  Haruhi Ando ,  Tomoaki Hasui ,  Toshiya Nishi

IPC: C07D413/10 ,  C07D491/08 ,  C07D413/12 ,  C07D413/14 ,  C07D263/32 ,  C07D413/04

CPC classification number: C07D263/32 ,  C07D413/04 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D491/08

Abstract: The present invention relates to a compound represented by the formula (I), which is useful as an agent for the prophylaxis or treatment of epilepsy, neurodegenerative disease and the like. In the formula (I), each symbol is as defined in the specification.